BioVersys AG Company

The Swiss biopharmaceutical company BioVersys focuses on research and development of small molecules which switch off drug resistance against existing antibiotics. With the company’s award-winning TRIC technology (Transcriptional Regulator Inhibitory Compounds) it is possible to restore the efficacy of approved antibiotics. By this, BioVersys addresses the high medical need for new treatments against life-threatening infections that emerged in recent years due to the resistance of bacterial strains against existing antibiotics. BioVersys' compounds will be used in combination with existing antibiotics, thereby renewing efficacy as well as intellectual property for the established drug. The current research focus is Nosocomial Infections (hospital acquired infections) and Tuberculosis.

In collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille, BioVersys is developing a preclinical candidate for the treatment of multidrug-resistant tuberculosis.


Technology: Precision Medicine
Industry: P3 Medicine
Headquarters: Basel, Basel-Stadt, Switzerland
Founded Date: 2008
Employees Number: 1-10
Funding Status: Early Stage Venture

Visit Website
Register and Claim Ownership